PO Box 221138, Chantilly, VA 20153-1138

FACSIMILE COVER LETTER

Confirmed Recipient Name:	Sender's Name/Title:				
Confirmed Recipient Fax Number:	Sender's Fax Number: 1-866-617-4900				
Confirmed Recipient Phone Number:	Sender's Phone Number:				
Date:	No. of Pages (including fax cover sheet)				
Notes:					
Please complete the attached form and return to the sender's fax number noted above. Thank you.					



Precertification Request for Prescription Medications

Fax this form to: 1-866-617-4900

For faster service, please call <MORG ADD 3>.

Patient Information		Prescriber Info	rmation				
Patient Name		Today's Date <cur date="" full=""></cur>					
<pt first="" name=""> <pt last="" name=""></pt></pt>							
Patient Insurance ID Num	ber	Physician Name					
		<evt prefix="" prov=""> <</evt>	EVT PROV FIRST NAME> <evt prov<="" td=""><td></td></evt>				
		LAST NAME>					
Patient Address, City, Stat		Physician Address					
<pt 1="" add=""> <pt 2="" add=""> <pt city=""> <pt state=""> <pt< td=""><td></td><td></td><td></td></pt<></pt></pt></pt></pt>							
ZIP>							
Home Telephone		M.D. Office Telephone Number					
<pt 2="" phone=""></pt>		<evt phone="" prov=""></evt>					
Gender	Patient Date of Birth	M.D. Office Fax Nur	mher				
☐ Male ☐ Female	<pt dob=""></pt>	<evt fax="" prov=""></evt>					
— Maio — Fornaio	Diagnosis and Mo		on .				
Medication	Diagnosic and in	Strength Frequency					
Wodlodion		Carongar	rioquerioy				
Expected Length of	Quantity	Day Supply	Is this a continuation of therapy,	_			
Therapy			how long has the patient been on				
			this medication?				
DI FACE CUIFOK ALL DO	VEO THAT APPLY						
PLEASE CHECK ALL BO		- d					
Diagnosis:	drug being prescribed for? ICD co	ode:					
	a diagnosis of cancer? Yes	□ No □					
	ons the patient has tried specific		specify helow:				
	including length of therapy for ea	_					
Drug(s) contraindica							
	toxicity, allergy) for each drug:						
☐ Is the request for a patient with one or more chronic conditions (e.g., psychiatric condition,							
Diabetes) who is stable on the current drug(s) and who might be at high risk for a significant							
adverse event with a medication change? If so, specify anticipated significant adverse event:							
Has the condition been confirmed by diagnostic testing? If so, please provider diagnostic							
Test and date: Does the patient have a clinical condition for which other alternatives are not recommended							
based on published guidelines or clinical literature? If so, please provide documentation:							
Does the patient require a specific dosage form (e.g., suspension, solution, injection)? If							
So, please provide dosage form:							
Are additional risk factors (e.g., GI risk, cardiovascular risk, age) present? If so, please							
provide risk factors:							
Other: Please provide additional relevant information:							
REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL DOCUMENTATION TO							
	SUPPORT USE OF THIS MEDICAITON. PLEASE COMPLETE CORRESPONDING SECTION FOR THE SPECIFIC						
DRUG/CLASS LISTED BELOW.							

Antifungals/Antiemetic (5-HT3) Agents/Celebrex/Erectile Dysfunction Agents/Proton Pump Inhibitors/Protopic Provigil/Nuvigil/Stimulants/Tazorax/Tretinoin Products/Triptans

FOR ANY DRUGS/CLASS NOT LISTED, PLEASE ATTACH ADDITIONAL INFORMATION, BUT CANNOT EXCEED TWO PAGES.

PRESCRIPTION BENEFIT PLAN MAY REQUEST ADDITIONAL INFORMATION OR CLARIFICATION, IF NEEDED, TO EVALUATE REQUESTS.

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that documentation supporting this information is available for review if requested by the health plan sponsor or delegate, or, if applicable, a state or federal regulatory agency. I understand that any person who knowingly makes or causes to be made a false record or statement that is material to a claim ultimately paid by the United States government or any state government may be subject to civil penalties and treble damages under both the federal and state False Claims Acts. See, e.g., 31 U.S.C. 3729-3733. **Prescriber Signature** Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents. PLEASE COMPLETE CORRESPONDING SECTION FOR THESE SPECIFIC DRUGS/CLASSES LISTED BELOW AND CIRCLE THE APPROPRIATE ANSWER OR SUPPLY RESPONSE. ☐ ANTIFUNGALS: LAMISIL, SPORANOX, PENLAC, DIFLUCAN Does the patient have secondary medical risk factors? Please specify which risk factor(s): If the patient has a diagnosis of Onychomycosis, does the infection involve the toenails, fingernails, or both? Please circle If the diagnosis is Tinea corporis or Tinea cruris, does the patient require systemic therapy or have more extensive superficial ☐ Yes ☐ No infections? ANTIEMETIC (5-HT3) AGENTS: (Ondansetron quantities of 12 or less per 30 days do not require a prior authorization) ☐ Yes ☐ No Is the patient receiving moderate to highly emetogenic chemotherapy? Monthly frequency: ___ ☐ Yes ☐ No Is the patient receiving radiation therapy? Monthly frequency: If the patient has a diagnosis of Hyperemesis Gravidarum, has the patient experienced an inadequate treatment response to two of the following medications? Vitamin B6, doxylamine, promethazine (Phenergan), trimethobenzamide (Tigan) or metoclopramide (Reglan)? — Yes — No Celebrex: Is the patient at risk for a severe NSAID-related gastrointestinal (GI) adverse event (e.g., NSAID associated gastric ulcer, GI ☐ Yes ☐ No ■ ERECTILE DYSFUNCTION: CIALIS, LEVITRA, VIAGRA, ALPROSTADIL Does the patient require nitrate therapy on a regulator OR on an intermittent basis, or is the patient currently taking another ED ☐ Yes ☐ No medication? If a diagnosis of erectile dysfunction, is it due to neurogenic etiology, vasculogenic etiology, psychogenic etiology or mixed etiology? Please circle. ☐ Yes ☐ No Is it being used for symptomatic Benign Prostatic Hyperplasia (BPH)? ☐ PROTON PUMP INHIBITORS: ☐ Yes ☐ No Does the patient have frequent and severe symptoms of GERD (e.g., heartburn, regurgitation)? Does the patient have atypical symptoms or complications of GERD (e.g., dysphagia, hoarseness, erosive ☐ Yes ☐ No Esophagitis)? ☐ PROTOPIC: ☐ Yes ☐ No Has the patient had a therapeutic failure of a topical corticosteroid? ☐ PROVIGIL/NUVIGIL: If the patient has a diagnosis of Obstructive Sleep Apena, is the patient currently using a continuous positive airway pressure ☐ Yes ☐ No machine or other device? ☐ STIMULANTS: AMPHETAMINES, METHYLPHENIDATES, STRATTERA ☐ Yes ☐ No Is this a renewal therapy? **☐** TAZORAC/TERTINOIN PRODUCTS: Has the patient tried and failed products from the following categories: Salicyclic Acid Prodcuts OR Benzoyl Peroxide

products?

TRIPTANS:

☐ Yes ☐ No

Is the patient currently using migraine prophylactic therapy (e.g., a mitriptyline, propranolo, timolol)?

Yes No